DK2019840T3 - Antagonist anti-human CD40 monoklonalt antistof. - Google Patents

Antagonist anti-human CD40 monoklonalt antistof.

Info

Publication number: DK2019840T3
Authority: DK; Denmark
Prior art keywords: human; monoclonal antibody; antagonist anti; antagonist; monoclonal
Prior art date: 2006-05-09

Application number

DK07747426.0T

Other languages

English (en)

Inventor

Hartog Marcel Theodorus Den

Neerven Ruprecht Jules Joost Van

Kevin Stuart Johnson

Robert Duncan Casson

Original Assignee

Fast Forward Pharmaceuticals B V

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-09

Filing date

2007-05-09

Publication date

2013-03-25

2007-05-09 Application filed by Fast Forward Pharmaceuticals B V filed Critical Fast Forward Pharmaceuticals B V

2013-03-25 Application granted granted Critical

2013-03-25 Publication of DK2019840T3 publication Critical patent/DK2019840T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK07747426.0T 2006-05-09 2007-05-09 Antagonist anti-human CD40 monoklonalt antistof. DK2019840T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US79881906P	2006-05-09	2006-05-09
EP06076028A EP1854810A1 (en)	2006-05-09	2006-05-09	Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
PCT/NL2007/050202 WO2007129895A2 (en)	2006-05-09	2007-05-09	Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody

Publications (1)

Publication Number	Publication Date
DK2019840T3 true DK2019840T3 (da)	2013-03-25

Family

ID=37635851

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07747426.0T DK2019840T3 (da)	2006-05-09	2007-05-09	Antagonist anti-human CD40 monoklonalt antistof.

Country Status (20)

Country	Link
US (1)	US8669352B2 (da)
EP (2)	EP1854810A1 (da)
JP (1)	JP5179474B2 (da)
KR (1)	KR101506348B1 (da)
CN (1)	CN101490086B (da)
AR (1)	AR060998A1 (da)
AU (1)	AU2007249031B9 (da)
BR (1)	BRPI0711355A2 (da)
CA (1)	CA2651565A1 (da)
CL (1)	CL2007001335A1 (da)
DK (1)	DK2019840T3 (da)
ES (1)	ES2406163T3 (da)
IL (1)	IL195196A (da)
MX (1)	MX2008014304A (da)
NO (1)	NO20085104L (da)
NZ (1)	NZ572756A (da)
RU (1)	RU2491295C2 (da)
TW (1)	TWI455947B (da)
WO (1)	WO2007129895A2 (da)
ZA (2)	ZA200810381B (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2044111E (pt)	2006-06-21	2014-11-12	Univ Colorado Regents	Abordagem seletiva do fator h do complemento para o tratamento de doenças
RS20120461A1 (sr)	2009-07-02	2013-06-28	Musc Foundation For Research Development	Metode za stimulaciju regeneracije jetre
AU2010292897B2 (en)	2009-08-06	2016-01-07	Genentech, Inc.	Method to improve virus removal in protein purification
EP2496259B1 (en)	2009-11-05	2017-02-22	Alexion Pharmaceuticals, Inc.	Treatment of paroxysmal nocturnal hemoglobinuria
WO2011109280A1 (en)	2010-03-05	2011-09-09	Lerner Research Institute	Methods and compositions to treat immune-mediated disorders
NZ602020A (en) *	2010-03-31	2014-05-30	Boehringer Ingelheim Int	Anti-cd40 antibodies
JP5986990B2 (ja)	2010-05-14	2016-09-06	ザリージェンツオブザユニヴァーシティオブコロラド，アボディコーポレート	改善された補体レセプター２（ｃｒ２）ターゲティング基
MX2012014975A (es)	2010-06-22	2013-03-12	Univ Colorado Regents	Anticuerpos al fragmento c3d de componente 3 de complemento.
AR083847A1 (es)	2010-11-15	2013-03-27	Novartis Ag	Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
PT2683406T (pt)	2011-03-11	2019-07-08	Beth Israel Deaconess Medical Ct Inc	Anticorpos anti-cd40 e utilização dos mesmos
US9475879B2 (en)	2011-04-21	2016-10-25	Bristol-Myers Squibb Company	Antibody polypeptides that antagonize CD40
SMT202000091T1 (it)	2011-10-13	2020-05-08	Bristol Myers Squibb Co	Polipeptidi anticorpali che antagonizzano cd40l
JP2015535212A (ja)	2012-08-17	2015-12-10	ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト	補体活性化を検出するための組成物および方法
US10413620B2 (en)	2012-08-17	2019-09-17	The Regents Of The University Of Colorado, A Body Corporate	Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
WO2014200349A1 (en)	2013-06-13	2014-12-18	Fast Forward Pharmaceutical B.V.	Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
EP2883883A1 (en)	2013-12-16	2015-06-17	Cardio3 Biosciences S.A.	Therapeutic targets and agents useful in treating ischemia reperfusion injury
WO2015134988A1 (en)	2014-03-07	2015-09-11	Bristol-Myers Squibb Company	Method of using antibody polypeptides that antagonize cd40 to treat ibd
CA2957502C (en)	2014-08-07	2021-07-20	Daiichi Sankyo Company, Limited	Anti-orai1 antibody
US20170233485A1 (en) *	2014-08-18	2017-08-17	Biogen Ma Inc.	Anti-cd40 antibodies and uses thereof
EP3229586B1 (en)	2014-12-10	2025-07-30	Regents of the University of Minnesota	Genetically modified cells, tissues, and organs for treating disease
RU2715597C2 (ru)	2015-05-29	2020-03-02	Эббви Инк.	Антитела к cd40 и способы их применения
HUE056769T2 (hu)	2015-09-04	2022-03-28	Primatope Therapeutics Inc	Humanizált anti-CD40 antitestek és felhasználásuk
BR112018006360A2 (pt)	2015-09-30	2018-10-09	Janssen Biotech Inc	anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
JP7461741B2 (ja)	2016-06-20	2024-04-04	カイマブ・リミテッド	抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
EP3601348A1 (en) *	2017-03-29	2020-02-05	Glycotope GmbH	Humanized anti-cd40 antibodies
US11525005B2 (en)	2017-06-01	2022-12-13	Jiangsu Hengrui Medicine Co., Ltd.	Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
AU2018361743A1 (en)	2017-11-03	2020-04-09	Novartis Ag	Anti-CD40 antibodies for use in treatment of Sjogren's syndrome
WO2019156565A1 (en)	2018-02-12	2019-08-15	Fast Forward Pharmaceuticals B.V.	Improved antagonistic anti-human cd40 monoclonal antibodies
US11780927B2 (en)	2018-04-13	2023-10-10	Novartis Ag	Anti-CD40 antibodies for use in prevention of graft rejection
CN112512572B (zh)	2018-04-20	2024-12-10	礼进生物医药科技（上海）有限公司	抗cd40抗体及其用途
MA52889A (fr)	2018-06-15	2021-04-21	Flagship Pioneering Innovations V Inc	Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
CN116063495A (zh)	2018-09-28	2023-05-05	礼进生物医药科技（上海）有限公司	具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
US20210355216A1 (en)	2018-10-05	2021-11-18	INSERM (Institut National de la Santé et de la Recherche Médicale	Methods and systems for controlling the agonistic properties of antibody variable domains by light
WO2020102454A1 (en)	2018-11-13	2020-05-22	Regents Of The University Of Minnesota	Cd40 targeted peptides and uses thereof
BR112021009835A2 (pt)	2018-11-30	2021-08-17	Jiangsu Hengrui Medicine Co., Ltd.	anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
MX2021006360A (es)	2018-11-30	2021-08-11	Jiangsu Hengrui Medicine Co	Composicion farmaceutica de anticuerpo cd40 y uso de la misma.
CA3125886A1 (en)	2019-01-11	2020-07-16	Novartis Ag	Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
EP3962493A2 (en)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V, Inc.	Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
AU2020267953A1 (en)	2019-05-08	2021-11-18	Novartis Ag	Anti-CD40 antibodies for use in treatment of T1DM and insulitis
CA3148890A1 (en)	2019-09-11	2021-03-18	Novartis Ag	A method for preventing human virus associated disorders in patients
US20230114107A1 (en)	2019-12-17	2023-04-13	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4172323A1 (en)	2020-06-29	2023-05-03	Flagship Pioneering Innovations V, Inc.	Viruses engineered to promote thanotransmission and their use in treating cancer
RS66868B1 (sr)	2021-01-28	2025-06-30	Regeneron Pharma	Kompozicije i postupci za lečenje sindroma oslobađanja citokina
US20220325287A1 (en)	2021-03-31	2022-10-13	Flagship Pioneering Innovations V, Inc.	Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko)	2021-06-29	2024-02-28	플래그쉽 파이어니어링 이노베이션스 브이, 인크.	타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2023020475A1 (en) *	2021-08-16	2023-02-23	Utc Therapeutics (Shanghai) Co., Ltd.	Cd40-targetting antibodies and uses thereof
EP4393937A4 (en)	2021-08-26	2025-12-31	Duality Biologics Shanghai Co Ltd	STEROID COMPOUND AND CONJUGATE OF THIS ONE
US12234294B2 (en)	2021-11-05	2025-02-25	Kiniksa Pharmaceuticals, Gmbh	Pharmaceutical composition of a humanized anti-CD40 antibody
WO2023198851A1 (en)	2022-04-14	2023-10-19	Institut National de la Santé et de la Recherche Médicale	Methods for controlling the tumor cell killing by light
WO2024077191A1 (en)	2022-10-05	2024-04-11	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en)	2023-01-09	2024-08-15	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
WO2025184567A1 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2026082692A1 (en) *	2024-10-15	2026-04-23	Les Laboratoires Servier	Antibodies to cd40 and compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9125768D0 (en)	1991-12-04	1992-02-05	Hale Geoffrey	Therapeutic method
DE69334064T2 (de)	1992-07-09	2007-05-24	Novartis Vaccines and Diagnostics, Inc., Emeryville	Antagonistische monoklonale Antikörper gegen menschliches CD40
US5874082A (en)	1992-07-09	1999-02-23	Chiron Corporation	Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
ATE283925T1 (de)	1996-07-23	2004-12-15	Tanox Pharma B V	Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
WO1998052976A1 (en) *	1997-05-21	1998-11-26	Biovation Limited	Method for the production of non-immunogenic proteins
US6051228A (en) *	1998-02-19	2000-04-18	Bristol-Myers Squibb Co.	Antibodies against human CD40
AR039067A1 (es) *	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US7563443B2 (en) *	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof

2006
- 2006-05-09 EP EP06076028A patent/EP1854810A1/en not_active Withdrawn
2007
- 2007-05-09 ES ES07747426T patent/ES2406163T3/es active Active
- 2007-05-09 WO PCT/NL2007/050202 patent/WO2007129895A2/en not_active Ceased
- 2007-05-09 US US11/801,344 patent/US8669352B2/en active Active
- 2007-05-09 MX MX2008014304A patent/MX2008014304A/es active IP Right Grant
- 2007-05-09 JP JP2009509467A patent/JP5179474B2/ja active Active
- 2007-05-09 BR BRPI0711355-2A patent/BRPI0711355A2/pt not_active IP Right Cessation
- 2007-05-09 CN CN200780025878.9A patent/CN101490086B/zh active Active
- 2007-05-09 DK DK07747426.0T patent/DK2019840T3/da active
- 2007-05-09 CA CA002651565A patent/CA2651565A1/en not_active Abandoned
- 2007-05-09 NZ NZ572756A patent/NZ572756A/xx not_active IP Right Cessation
- 2007-05-09 AR ARP070102017A patent/AR060998A1/es not_active Application Discontinuation
- 2007-05-09 KR KR1020087030080A patent/KR101506348B1/ko active Active
- 2007-05-09 CL CL2007001335A patent/CL2007001335A1/es unknown
- 2007-05-09 EP EP07747426A patent/EP2019840B1/en active Active
- 2007-05-09 AU AU2007249031A patent/AU2007249031B9/en active Active
- 2007-05-09 ZA ZA200810381A patent/ZA200810381B/xx unknown
- 2007-05-09 TW TW096116566A patent/TWI455947B/zh not_active IP Right Cessation
- 2007-05-09 RU RU2008148303/10A patent/RU2491295C2/ru not_active IP Right Cessation
2008
- 2008-11-10 IL IL195196A patent/IL195196A/en active IP Right Grant
- 2008-12-09 NO NO20085104A patent/NO20085104L/no not_active Application Discontinuation
2009
- 2009-12-23 ZA ZA2009/09185A patent/ZA200909185B/en unknown

Also Published As

Publication number	Publication date
BRPI0711355A2 (pt)	2011-09-27
ZA200909185B (en)	2012-07-25
CL2007001335A1 (es)	2008-01-18
AU2007249031B2 (en)	2012-09-27
AR060998A1 (es)	2008-07-30
HK1131627A1 (en)	2010-01-29
JP5179474B2 (ja)	2013-04-10
EP1854810A1 (en)	2007-11-14
JP2009536522A (ja)	2009-10-15
WO2007129895A2 (en)	2007-11-15
WO2007129895A3 (en)	2008-12-31
ES2406163T3 (es)	2013-06-05
CA2651565A1 (en)	2007-11-15
CN101490086B (zh)	2014-03-05
RU2008148303A (ru)	2010-06-20
ZA200810381B (en)	2010-03-31
AU2007249031B9 (en)	2013-01-24
WO2007129895A9 (en)	2009-02-19
AU2007249031A1 (en)	2007-11-15
US8669352B2 (en)	2014-03-11
RU2491295C2 (ru)	2013-08-27
KR20090029203A (ko)	2009-03-20
IL195196A (en)	2016-02-29
US20080085531A1 (en)	2008-04-10
NO20085104L (no)	2009-02-09
IL195196A0 (en)	2011-08-01
EP2019840B1 (en)	2012-12-19
CN101490086A (zh)	2009-07-22
TW200815471A (en)	2008-04-01
EP2019840A2 (en)	2009-02-04
NZ572756A (en)	2012-10-26
KR101506348B1 (ko)	2015-04-08
TWI455947B (zh)	2014-10-11
MX2008014304A (es)	2008-11-26

Publication	Publication Date	Title
NO344963B1 (no)	2020-08-03	Humanisert antistoff
ZA200810381B (en)	2010-03-31	Antagonistic anti-human CD40 monoclonal antibody
SG10201404801YA (en)	2014-09-26	Monoclonal antibody
NL1027975A1 (nl)	2005-07-12	Antilichamen tegen MAdCAM.
IS8596A (is)	2007-01-24	Mótefni gegn CD154
LTC1776142I2 (lt)	2022-07-11	IL-17 antagonistiniai antikūnai
LT3656793T (lt)	2022-03-10	Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
DE602006017373D1 (de)	2010-11-18	Madcam-antikörper
BRPI0817250A2 (pt)	2014-06-17	Anticorpo anti-receptor da il-6.
NO20076607L (no)	2008-02-27	TWEAK - bindende antistoff
DK1964852T3 (da)	2013-07-08	Anti-ilt7-antistof
HRP20150176T1 (xx)	2015-03-27	Protutijela protiv miostatina
BRPI0807991A2 (pt)	2014-06-17	Anticorpos anti-il-23r elaborados.
LTPA2016026I1 (lt)	2016-09-26	Anti-il-17 antikūnai
NO20071430L (no)	2007-05-15	Anti-OX4OL antistoffer
IL193871A0 (en)	2011-08-01	Humanized anti-cd20 monoclonal antibody
DK2066695T3 (da)	2013-06-10	Anti-myostatin-antistoffer
BRPI0907532A2 (pt)	2015-07-28	Anticorpos anti-c5ar humanizados
DK2292663T3 (da)	2013-11-04	Antagonistiske human-let-specifikke, humane monoklonale antistoffer
DK2225280T3 (da)	2014-05-26	Bivalente, bispecifikke antistoffer
BRPI0821405A2 (pt)	2015-06-16	Anticorpos biespecíficos, bivalentes
BRPI0821375A2 (pt)	2015-06-16	Anticorpos biespecíficos, bivalentes
BRPI0814111A2 (pt)	2015-02-03	Anticorpo monoclonal citotóxico anticâncer
SG10201601279SA (en)	2016-03-30	Monoclonal Antibody STRO-4
IL204835A0 (en)	2010-11-30	Humanized antibody